Palbociclib Approved for HR-positive, HER2-positive Advanced Breast Cancer
Palbociclib is the first CDK4/6 inhibitor approved for HR-positive, HER2-positive advanced breast cancer. The U.S. Food and Drug Administration...
Progress Against Cancer
Palbociclib is the first CDK4/6 inhibitor approved for HR-positive, HER2-positive advanced breast cancer. The U.S. Food and Drug Administration...
Afamitresgene autoleucel was granted full approval with an expanded indication for certain adult and pediatric patients with advanced synovial...
The FDA approved capivasertib with abiraterone and prednisone for adults whose metastatic prostate cancer may be sensitive to hormone...
Under new approval, the drug can be given with immunotherapy to help reduce risk of recurrence after surgery in...
The FDA approved durvalumab with Bacillus-Calmette Guérin for patients with high-risk, BCG-naïve non-muscle invasive bladder cancer. The U.S. Food...
The FDA approved pivekimab sunirine-pvzy for the treatment of the rare blood cancer BPDCN. The U.S. Food and Drug...
Datopotamab deruxtecan-dlnk was approved to treat PD-1/PD-L1 inhibitor-ineligible, advanced triple-negative breast cancer. The U.S. Food and Drug Administration (FDA)...
The FDA has approved fam-trastuzumab deruxtecan-nxki for neoadjuvant or adjuvant treatment of HER2-positive early-stage breast cancer. The U.S. Food...
The FDA has approved atezolizumab or atezolizumab and hyaluronidase-tqjs as adjuvant therapy for muscle-invasive bladder cancer. The U.S. Food...
The FDA approved oral decitabine and cedazuridine with venetoclax for newly diagnosed acute myeloid leukemia in older patients. The...